In its software, Lykos describes MDMA as being a catalyst for the therapeutic procedure, And that's why it gained so much focus. That isn't predicted to become as much of a maintain-up for other psychedelics, although. “The rest of us are studying molecules that do not require the same degree of therapy,” suggests Kabir Nath, CEO of Compass Pat